Neuroscience and Behavioral Physiology

, Volume 29, Issue 2, pp 217–221 | Cite as

Synaptic contacts in schizophrenia: Studies using immunocytochemical identification of dopaminergic neurons

  • N. S. Kolomeets
  • N. A. Uranova


Immunocytochemical identification of dopaminergic neurons was performed using an immunoperoxidase method employing antibodies to tyrosine hydroxylase. The ultrastructure of synaptic contacts on dopaminergic (tyrosine hydroxylase immunopositive (TP) cells) neurons was investigated in the substantia nigra in the brains of four patients with schizophrenia and three mentally healthy subjects (controls). The substantia nigra of schizophrenia patients differed from control material in showing the following changes in the ultrastructure of presynaptic terminals contacting TP neurons: reductions in the size of terminals with dense matrix and poorly distinguished vesicles; swelling of terminals with small numbers of vesicles displaced from the active zone of the synapse; hyperplasia of mitochondria in some presynaptic boutons; appearance of membranous lamellar structures within or adjacent to presynaptic boutons. These changes to terminals were located mostly on the distal (small and intermediate) TP dendrites in the compact zone of the substantia nigra, where nearly all the dendrites detected belonged to dopaminergic neurons and the altered terminals formed asymmetrical contacts with short active zones. In the reticular part of the substantia nigra of schizophrenic patients, changes in the ultrastructure of presynaptic terminals were relatively rare; altered terminals contacted both tyrosine hydroxylase immunopositive as well as with the tyrosine hydroxylase immunonegative dendrites located in this structure.


Schizophrenia Tyrosine Hydroxylase Substantia Nigra Dopaminergic Neuron Schizophrenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    V. A. Agafonov and Yu. I. Savulev,Zh. Nevropatol. Psikhiatr.,77, No. 7, 1074–1077 (1977).PubMedGoogle Scholar
  2. 2.
    N. A. Uranova and O. I. Levite,Zh. Nevropatol. Psikhiatr.,87, No. 7, 1017–1024 (1987).PubMedGoogle Scholar
  3. 3.
    N. A. Uranova,The Dopaminergic System of the Brain in Schizophrenia (An Ultrastructural Morphological Study) [in Russian], Author's Abstract of Thesis for Doctorate in Medical Sciences, Moscow (1995).Google Scholar
  4. 4.
    F. M. Benes, L. Davison, and E. D. Bird,Arch. Gen. Psychiatr.,43, No. 1, 31–36 (1986).PubMedGoogle Scholar
  5. 5.
    F. M. Benes, Y. McSparren, E. D. Bird, et al.,Arch. Gen. Psychiatr.,48, 996–1001 (1991).PubMedGoogle Scholar
  6. 6.
    E. D. Bird, E. G. Spores, Y. Barnes, et al.,Lancet,11, 1157–1158 (1977).CrossRefGoogle Scholar
  7. 7.
    B. Bogerts, J. Hantsch, and M. Herzer,Biol. Psychiatr.,18, No. 9, 951–969 (1983).Google Scholar
  8. 8.
    J. P. Bolam and Y. Smith,Brain Res.,529, 57–78 (1990).PubMedCrossRefGoogle Scholar
  9. 9.
    M. Carlsson and A. Carlsson,Trends Neurosci.,13, 272–276 (1990).PubMedCrossRefGoogle Scholar
  10. 10.
    E. T. Colon,Acta Neuropathol.,20, 1–10 (1972).PubMedCrossRefGoogle Scholar
  11. 11.
    T. J. Crow,Brit. J. Psychiatr.,139, 251 (1981).CrossRefGoogle Scholar
  12. 12.
    T. J. Crow, E. C. Johnstone, A. Longden, et al., “Dopamine,” in:Advances in Biochemical Pharmacology P. J. Roberts (Ed.), New York (1978), pp. 301–309.Google Scholar
  13. 13.
    K. L. Davis, R. S. Kahn, G. Ko, et al.,Am. J. Psychiatr.,148, No. 11, 1474–1486 (1991).PubMedGoogle Scholar
  14. 14.
    H. Evans, C. Calopi, T. Wheelan, et al.,Neurosci. Lett.,35, No. 1, 17–25 (1989).Google Scholar
  15. 15.
    A. V. P. Mackay, L. L. Iversen, M. Lasson, et al.,Arch. Gen. Psychiatr,32, 991–997 (1982).Google Scholar
  16. 16.
    R. Martinez-Murillo, R. M. Villalba, and J. Rodrigo,Neurosci. Lett.,96, 121–126 (1989).PubMedCrossRefGoogle Scholar
  17. 17.
    I. Mendez, K. Elisevich, and B. A. Flumerfelt,Brain Res.,604, 274–284 (1993).CrossRefGoogle Scholar
  18. 18.
    S. Nedergaard, J. P. Bolam, and S. A. Greenfield,Nature,333, 174–177 (1988).PubMedCrossRefGoogle Scholar
  19. 19.
    C. Nitsch, K. Mews, A. Wagner, et al.,Acta Anat.,119, 193–202 (1984).PubMedCrossRefGoogle Scholar
  20. 20.
    G. P. Reynolds and A. Y. Cutts,Schizophrenia Res.,6, 137 (1992).CrossRefGoogle Scholar
  21. 21.
    H. Tokuno, T. Moriizumi, M. Kudo, et al.,Neurosci. Lett.,85, 1–4 (1988).PubMedCrossRefGoogle Scholar
  22. 22.
    A. N. Van den Pol, A. D. Smith, and J. F. Powell,Brain Res.,348, 146–154 (1985).PubMedCrossRefGoogle Scholar
  23. 23.
    D. R. Weinberger,TINS,11, No. 8, 367–370 (1988).PubMedGoogle Scholar

Copyright information

© Kluwer Academic/Plenum Publishers 1999

Authors and Affiliations

  • N. S. Kolomeets
  • N. A. Uranova
    • 1
  1. 1.Laboratory of Clinical Neuromorphology, Science Research Institute Mental HealthRussian Academy of Medical SciencesMoscow

Personalised recommendations